[1]房伟,马云涛,马世勋,等.复方苦参注射液联合紫杉醇和替吉奥治疗晚期胃癌的临床疗效观察[J].西部中医药,2021,34(04):100-104.[doi:10.12174/j.issn.2096-9600.2021.04.25]
　FANG Wei,MA Yuntao,MA Shixun,et al.Observation on Clinical Effects of Compound Kushen Injection Combined with Paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsules in the Treatment for Advanced Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(04):100-104.[doi:10.12174/j.issn.2096-9600.2021.04.25]
点击复制

复方苦参注射液联合紫杉醇和替吉奥治疗晚期胃癌的临床疗效观察
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年04期
页码:
100-104
栏目:
衷中参西
出版日期:
2021-04-15

文章信息/Info

Title:
Observation on Clinical Effects of Compound Kushen Injection Combined with Paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsules in the Treatment for Advanced Gastric Cancer
作者:
房伟, 马云涛, 马世勋, 李渊, 李一平, 苗长丰
甘肃省人民医院，甘肃 兰州 730030
Author(s):
FANG Wei, MA Yuntao, MA Shixun, LI Yuan, LI Yiping, MIAO Changfeng
Gansu Provincial Hospital, Lanzhou 730030, China
关键词:
晚期胃癌; 紫杉醇; 替吉奥; 复方苦参注射液; 临床疗效
Keywords:
advanced gastric cancer; PTX; S-1; compound injection; clinical effects
分类号:
R735
DOI:
10.12174/j.issn.2096-9600.2021.04.25
摘要:
目的观察复方苦参注射液联合紫杉醇（PTX）和替吉奥（S-1）治疗晚期胃癌的短期疗效和毒副反应。 方法选择晚期胃癌患者50例，随机分为观察组和对照组，每组25例。观察组：紫杉醇135 mg/m2，静脉滴注，第1天；替吉奥胶囊每日80 mg，口服，每日2次，1～14天，停药1周；复方苦参注射液12 mL，加入200 mL0.9%氯化钠注射液稀释，静脉滴注，1～14天，停药1周。对照组：紫杉醇135 mg/m2，静脉滴注，第1天；替吉奥胶囊每日80 mg，口服，每日2次，1～14天，停药1周。21天为1个周期，每例至少完成4个治疗周期。两组疗效评价参照WHO近期疗效评价标准；不良反应评价参照抗癌药物毒副反应的分度标准。 结果观察组有效率为56.0%（14/25），临床受益率为84.0%（21/25）；对照组有效率为44.0%（11/25），临床受益率为72.0%（18/25）。两组间有效率及临床受益率比较，差异均无统计学意义（P＞0.05）。两组患者化疗后各种不良反应发生率比较，差异均无统计学意义（P＞0.05）。 结论复方苦参注射液联合紫杉醇和替吉奥治疗晚期胃癌具有良好的临床疗效，且不增加化疗药物不良反应。
Abstract:
ObjectiveTo observe short-term effects and toxic reaction of compound Kushen injection combined with paclitaxel (PTX) and tegafur gimeracil oteracil potassium capsules (S-1) in the treatment for advanced gastric cancer. MethodsFifty patients were randomized into the observation group and the control group, 25 cases each group. The observation group: PTX, 135 mg/m2, intravenous dripping, at the first day; S-1 80 mg/d, oral administration, bid, 1~14 days, drug withdrawal for one week; compound Kushen injection, 12 mL, adding 200 mL,0.9% sodium chloride injection to dilute, intravenous dripping, 1~14 days, drug withdrawal for one week. The control group: PTX, 135 mg/m2, intravenous dripping, at the first day; S-1 80 mg/d, oral administration, bid, 1~14 days, drug withdrawal for one week. 21 days were one course, each case must finish four therapeutic cycles at least. Clinical effects were assessed in light of evaluation criteria for short-term efficacy of WHO; toxic reactions were assessed according to classification criteria for toxic reaction of anti-cancer drugs(WHO). ResultsThe effective rate of the observation group was 56.0%(14/25), clinical benefit rate was 84.0%(21/25); the effective rate of the control group was 44.0%(11/25), clinical benefit rate was 72.0%(18/25). The difference had no statistical meaning in the comparisons of the effective rate and clinical benefit rate between both groups. The difference had no statistical meaning in the comparisons of the incidences of adverse reaction after chemotherapy between both groups (P>0.05). ConclusionCompound Kushen injection combined with PTX and S-1 could gain better effects in the treatment for advanced gastric cancer, and it would not arouse adverse reaction of chemotherapeutic agents.

相似文献/References:

[1]狄晓鸿,吕瑞.TP化疗方案联合参芪扶正注射液治疗晚期卵巢癌的临床观察[J].西部中医药,2015,28(08):1.
[2]王玥,栗枭杰,吴朝旭,等.贫血对晚期胃癌患者预后及生活质量的影响[J].西部中医药,2023,36(11):101.[doi:10.12174/j.issn.2096-9600.2023.11.22]
　WANG Yue,LI Xiaojie,WU Chaoxu,et al.Influence of Anemia on the Prognosis and Quality of Life of Patients with Advanced Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2023,36(04):101.[doi:10.12174/j.issn.2096-9600.2023.11.22]

备注/Memo

备注/Memo:
房伟（1983—），男，硕士学位，主治医师。研究方向：胃肠道肿瘤的防治。甘肃省自然科学基金（1508RJZA043）。
更新日期/Last Update: 2021-04-15